StockData
INKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

MiNK Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$9.56+0.15 (+1.59%)

Close on Oct 19, 2026

Market cap
$48.02M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Dec 7, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 13, 2026Before market open–$0.62–
Q1 FY2026
Ended Mar 31, 2026
May 15, 2026Before market open–$-0.57–
Q4 FY2025
Ended Dec 31, 2025
Mar 31, 2026Before market open–$-0.56–
Q3 FY2025
Ended Sep 30, 2025
Dec 8, 2025After market close–$0.65–
Q2 FY2025
Ended Jun 30, 2025
Aug 14, 2025Before market open–$1.06–
Q1 FY2025
Ended Mar 31, 2025
May 15, 2025Before market open–$-0.70–
Q4 FY2024
Ended Dec 31, 2024
Mar 18, 2025Before market open–––
Q3 FY2024
Ended Sep 30, 2024
Nov 14, 2024Before market open–$-0.05–
Q2 FY2024
Ended Jun 30, 2024
Aug 13, 2024Before market open–$-0.07–
Q1 FY2024
Ended Mar 31, 2024
May 14, 2024Before market open–$-0.11–
Q4 FY2023
Ended Dec 31, 2023
Mar 21, 2024Before market open–$0.16–

Press releases

Announcements MiNK Therapeutics filed with the SEC